XAIR · Beyond Air, Inc.

Beyond Air, Inc. has executed a significant leadership transition with the resignation of Steven A. Lisi, who served as CEO and Director, effective March 27, 2026. Mr. Lisi led the company for nine years, guiding the development and launch of the LungFit PH system. The Board stated his resignation was not due to any disagreement regarding operations, policies, or practices. To facilitate a smooth transition, the Company entered into a Separation and Release of Claims Agreement with Mr. Lisi. The agreement provides for total separation payments of $650,000, representing one year of his base salary, paid over 12 months, along with 12 months of COBRA premium coverage. A notable term for investors is the acceleration of all unvested equity awards, which immediately vested upon separation, and the extension of the exercise period for all equity awards to 24 months post-separation.

Succeeding Mr. Lisi is Robert Goodman, who has served as a Director since June 2025 and Chief Commercial Officer since November 2025. Mr. Goodman brings over 25 years of commercial experience in the healthcare sector, including leadership roles at BioTelemetry, Philips Healthcare, and Pfizer. The Board highlighted his role in transforming the Company's business strategy and his expertise in scaling commercial operations. As of the filing date, the Company has not finalized a new employment agreement or compensation arrangements for Mr. Goodman, indicating that terms for the new CEO are currently under negotiation. The Company expects a seamless transition with no disruption to operations or strategic priorities.